# FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Source: https://onco.cc/trials/nct05749588/  
OnCo record `nct05749588` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, everolimus, TQB2102 and TQB2868 in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

FUSCC Refractory TNBC Platform Study (FUTURE2.0) is a phase 2, interventional study registered as NCT05749588 by Fudan University, with a registry enrolment figure of 120 participants, started 2023-03-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: A1: SHR-A1811; A2: SHR-A1811 with Camrelizumab with famitinib; B1: TROP2 ADC; B2: TROP2 ADC with Camrelizumab; C1: SHR-A1811; C2: SHR-A1811 with BP102; D1: TROP2 ADC; D2: TROP2 ADC with BP102; E1: SHR-A1811; F1: TROP2 ADC; G1: SHR-A1811; H1: TROP2 ADC; E2: SHR-A1811 with everolimus; TQB2102 with TQB2868. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negat". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05749588
- Phase: 2
- Setting: Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）
- Sponsor: Fudan University
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05749588: https://clinicaltrials.gov/study/NCT05749588

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Everolimus](https://onco.cc/drugs/everolimus/), [TQB2102](https://onco.cc/drugs/tqb2102/), [TQB2868](https://onco.cc/drugs/tqb2868/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05749588.json